Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Q2 FY25 Earnings Presentation
72 slides from Jubilant Pharmova's earnings presentation, Oct 25, 2024
Slide 1: Exchange cover letter: Press Release along with Earnings Presentation
October 25, 2024 BSE Limited, National Stock Exchange of India Limited, Floor 25, P. J. Towers Exchange Plaza, Bandra-Kurla Complex, Dalal Street, Fort Bandra (E), Mumbai - 400 001 Mumbai - 400051 Scrip Code: 530019 Symbol: JUBLPHARMA Sub: Press Release along with Earnings Presentation Ref: Regulati
Slide 2: Jubilant Pharmova Q2 & H1 FY25 Results press release
Jubilant Pharmova Limited 1A, Sector 16A, Noida – 201301, India Tel.: +91 120 4361000 PRESS RELEASE www.jubilantpharmova.com Noida, Oct 25, 2024 JUBILANT PHARMOVA – Q2 & H1’FY25 RESULTS Sustaining growth momentum, EBITDA margin expansion & Net debt/EBITDA improvement Particulars (Rs. Cr.) Q2’FY24 Q1
Slide 3: Segmental Business Performance
Segmental Business Performance Radiopharma - Leading Radiopharmaceutical manufacturer & 2nd largest Radiopharmacy network in the US Radiopharmaceuticals Q2’FY25 revenue stood at Rs. 251 Cr. with EBITDA margins at 48%. The business continues to maintain a strong position in the high margin SPECT imag
Slide 4: About Jubilant Pharmova Limited
We plan to launch six to eight products per annum in our US and non-US international markets. We also plan to start the supply of approved products from Roorkee facility to the US market in H2’FY25. There are 35 ANDAs in the approval pipeline for the US. In our last update, we had communicated that
Slide 5: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 6: Earnings Presentation Q2'FY25
Earnings Presentation Q2’FY25
Slide 7: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 8: Jubilant Bhartia Group - Snapshot
Jubilant Bhartia Group - Snapshot Jubilant Bhartia Group founded by Shyam S. Bhartia and Hari S. Bhartia, leading industrialists from India Strong presence in diverse sectors like Pharmaceuticals, Life Science Ingredients, Contract Research & Development Services and Therapeutics, Performance Polyme
Slide 9: Company Snapshot
Company Snapshot A global pharmaceutical company with strong team of approx. 5,500 multicultural people & Total Income at Rs. 7,006 Cr. (TTM*) 1 2 3 4 5 6 Allergy CDMO PROPRIETARY Radiopharma CRDMO GENERICS Immunotherapy Sterile Injectables NEW DRUGS • • Serves regulated • • Leading Leading contract
Slide 10: Revenue Split – H1'FY25 (BU wise)
Revenue Split – H1’FY25 ( BU wise ) 9% Radiopharma 15% Allergy Immunotherapy 47% CDMO - SI CRDMO 18% Generics 10% 5
Slide 11: Global Manufacturing & Research Footprint
Global Manufacturing & Research Footprint World class manufacturing facilities, 2 state of the art research centers & 46 radiopharmacies Kirkland, Montreal, Canada Kirkland, Montreal, Canada Spokane, Washington, USA Spokane, Washington, USA CDMO – SteriIe Injectables Radiopharmaceuticals CDMO – Ster
Slide 12: Jubilant Pharmova - Q2'FY25
Jubilant Pharmova - Q2’FY25 Announced Strategic partnership with Pierre Fabre; Improved overall financial performance YoY 1 2 3 4 5 6 INNOVATE STRENGTHEN GROW BUILD STEER DISCOVER Allergy CDMO PROPRIETARY Sterile Injectables CRDMO GENERICS Radiopharma Immunotherapy NEW DRUGS • Continued growth • Con
Slide 13: Radiopharmaceuticals: Growing role in treatment of life threatening diseases
1 Radiopharmaceuticals Growing role in treatment of life threatening diseases Single-photon Emission Positron Emission Radiopharmaceutical Computed Tomography Tomography Therapeutics (SPECT Imaging) (PET Imaging) (Tx) • Uses “low-energy” radio • Radiation is systemically or locally delivered • Uses
Slide 14: US radiopharmaceutical market expected to reach approx. USD 20 Bn by 2030
Radiopharmaceuticals US radiopharmaceutical market is expected to reach approx. USD 20 Bn. by 2030, growing at a CAGR of 20 %+ US Radiopharmaceutical Market (USD Bn.) Growth Drivers and Key Trends • Growth driven by superior imaging and therapeutics profiles, new emerging isotopes with low off targe
Slide 15: Consolidated market with high entry barriers
Radiopharmaceuticals Consolidated market with high entry barriers Stringent manufacturing & regulatory environment Adherence with extensive license framework. Stringent manufacturing set up required to handle isotopes Managing time sensitive Forward integration logistics with radiopharmacies Radioac
Slide 16: Wide radiopharmaceutical portfolio
Radiopharmaceuticals We are one of largest manufacturer in the addressable market in the US with a wide radiopharmaceutical portfolio Organ Type Product Key Indication Dx Tc99m-DTPA Pulmonary Embolism SPECT Lung Key Differentiators Dx Tc99m-MAA Pulmonary Perfusion SPECT Localizing metastases Dx SPEC
Slide 17: Market leadership in select products - MAA, DTPA and I-131
Radiopharmaceuticals Market leadership in select products - MAA, DTPA and I-131 Draximage ® MAA Draximage ® DTPA HICON® Sodium Iodine I 131 Solution USP MAA is used in the perfusion DTPA is used to assess HICON® is a radioactive phase of a ventilation/perfusion pulmonary ventilation function in ther
Slide 18: Innovation Leadership in Ruby-Fill
Radiopharmaceuticals Innovation Leadership in Ruby - Fill ®, Gaining market share consistently Growing Cardiac PET Market in the US Ruby-Fill ® Rubidium 82 generator and Elusion System ~420 • The RUBY-FILL® Rubidium 82 Generator ~375 contains accelerator produced Strontium-82, ~335 ~300 which decays
Slide 19: Ruby-Fill and Robust product pipeline to fuel future growth
Radiopharmaceuticals Ruby-Fill® and Robust product pipeline to fuel future business growth New Product led volume Ruby-Fill® PET & SPECT Development of therapeutic growth Growth potential Product Pipeline product - MIBG • Gain market share in the • Target to launch new • Completed patient dosing gro
Slide 20: Radiopharmaceuticals: Driving revenue growth
Radiopharmaceuticals Driving revenue growth Particulars ( Rs. Cr.) Q2’FY24 Q1’FY25 Q2’FY25 Y-o-Y H1'FY24 H1'FY25 Y-o-Y • Q2’FY25 revenue stable YoY. Overall H1’FY25 revenue grew by 13% YoY on the back of new product sales in Sulfur Colloid and growth in Revenue 251 262 251 0% 455 513 13% Ruby-Fill ®
Slide 21: US Radiopharmacy market expected to grow
Radiopharmacy US Radiopharmacy market is expected to grow on the back of novel PET & Therapeutic products SPECT Radiopharmacy PET Radiopharmacy Growth Drivers and Key Trends • Radiopharmacy dispenses and distributes radiopharmaceutical products • Consolidated market in US with top 3 radiopharmacy ne
Slide 22: Consolidated market with high barriers to entry
Radiopharmacy Consolidated market with high barriers to entry Consolidated Market Barriers to Entry Stringent Regulations # of radio # of 1 pharmacies SPECT PET hospitals Each treatment site is required to obtain a license from pharmacies pharmacies served in in the US the US Nuclear Regulatory Comm
Slide 23: 2nd largest radiopharmacy network in the US
Radiopharmacy 2nd largest radiopharmacy network in the US 46 nuclear USP<825> pharmacies JDR network is USP 825 including SPECT Portland WD compliant. and PET MT ND ME OR MN VT ID Saginaw NH 1,800 SD Minneapolis WI Detroit Wilkes NY Boston >100 WY MI Phila- RI radiopharmaceutical number of Barre PA
Slide 24: Investing in PET radiopharmacy network
Radiopharmacy Investing in PET radiopharmacy network throughout the US to drive growth & profitability PET Radiopharmacy • Plans to invest USD 50 Mn. to expand PET radiopharmacy network by adding Six (6) sites in strategic locations throughout US • Investment shall position the company in the growin
Slide 25: Expand Radiopharmacy network, ride on volume & new product growth
Radiopharmacy Expand Radiopharmacy network, Ride on volume & new product led industry growth Radiopharmacy Network New Product led volume Enhance Operational Expansion growth Efficiencies • Expand PET radiopharmacy • Drive revenue on the back of • Further strengthen performance network by adding six
Slide 26: Radiopharmacy: Volume to drive revenue growth
Radiopharmacy Volume to drive revenue growth & operational efficiency to drive margin expansion Particulars ( Rs. Cr.) Q2’FY24 Q1’FY25 Q2’FY25 Y-o-Y H1'FY24 H1'FY25 Y-o-Y • Q2’FY25 revenue grew YoY on the back of increase in volume from new products Revenue 490 570 568 16% 977 1,139 17% • Q2’FY25 EB
Slide 27: Allergy Immunotherapy global market
2 Allergy Immunotherapy Global market poised to reach USD 3 Bn. by 2028, growing at a CAGR of ~ 7% Most Common Allergies in US (2023) Global Allergy Immunotherapy Market ( USD Bn. ) Others Insect 6.4% 6.4% 3.0 Food 2.2 10.0% Pollen 2.7 40.0% 2.0 Pet 10.9% 0.2 0.3 Mold Drug 2023 2028 12.7% 13.6% Non-
Slide 28: Jubilant is #2 player in US Sub-Cutaneous Allergy Immunotherapy
Allergy Immunotherapy Jubilant is #2 player in the US Sub-Cutaneous Allergy Immunotherapy market with strong entry barriers Strong Entry Barriers Key Differentiators • Highly concentrated US market with well established • # 2 player in the US SCIT allergy market & Sole Supplier players of Venom immu
Slide 29: Balanced Product Portfolio
Allergy Immunotherapy Balanced Product Portfolio Venom Extracts Allergenic Extracts Skin Testing Devices • Allergenic extracts (over 200 • Multiple skin test system includes • Venom extracts includes products for ComforTen, Quintest and Quintip products) includes products for Honey Bee, White-Faced
Slide 30: Three pronged growth strategy
Allergy Immunotherapy Moving ahead on three pronged growth strategy Enlarge US Venom Segment Gain market share in US Penetrate outside US market Allergenic extracts • Create customer awareness on • Use Venom products to gain • Penetrate the Europe market on the the Bee sting allergy through customer
Slide 31: Allergy Immunotherapy: Sustained growth momentum & margin expansion
Allergy Immunotherapy Sustained growth momentum & margin expansion • Q2’FY25 revenue lower YoY due to delay in Particulars ( Rs. Cr.) Q2’FY24 Q1’FY25 Q2’FY25 Y-o-Y H1'FY24 H1'FY25 Y-o-Y product launches in the new markets outside of US by our partners Revenue 179 168 170 (5%) 330 338 2% • Q2’FY25 EB
Slide 32: Demand expected to outpace supply by 2027
3 CDMO - Sterile Injectables Demand expected to outpace the supply by 2027 Global CDMO-SI Market Size (in USD Bn.) Growth Drivers & Key Trends 20 • Increase in demand: Increasing number of 17 drugs/injectable in development pipeline driven by 16 biologics (65%+ of current pipeline) and LOEs 14 13 •
Slide 33: Structurally attractive market with key differentiators
CDMO - Sterile Injectables Structurally attractive market with key differentiators driving our growth Strong Entry Barriers Key Differentiators • Majority of commercial contracts are typically long • Deep and long-term relationships with our customers duration (typically 3 years or more with auto re
Slide 34: Collaborative partner with unique capabilities & strong customer relationships
CDMO - Sterile Injectables Collaborative partner with unique capabilities & strong customer relationships Full Suite of • Can handle Vial size from 2ml to 100 ml with batch size up to 2,000 ltr. Services • Full suite of services including sterile fill and finish (Liquid & Freeze dried), Ophthalmic (
Slide 35: Doubling of capacity at Spokane on track
CDMO - Sterile Injectables Doubling of capacity with state of the art technology at Spokane on track; Incremental revenue potential of $160m - $180m Timeline FY’24 FY’25 FY’26 FY’27 FY’28 LINE 3 Installation Media Fill Tech Transfer Commercial Production LINE 4 Design Construction Installation Media
Slide 36: CDMO Sterile Injectables: Driving Revenue growth
CDMO - Sterile Injectables Driving Revenue growth • Q2’FY25 revenue stable YoY despite CMO Particulars ( Rs. Cr.) Q2’FY24 Q1’FY25 Q2’FY25 Y-o-Y H1'FY24 H1'FY25 Y-o-Y Montreal plant under remediation Revenue 301 324 302 0% 555 626 13% • Q2’FY25 EBITDA & EBITDA margins increased YoY due to retrospecti
Slide 37: CRDMO: Drug Discovery Services, CDMO & API markets
4 CRDMO: Drug Discovery Services, CDMO & API Both Drug Discovery Services and API/Formulation Development markets are expected to grow at ~5-6% CAGR Growth Drivers for Drug Discovery Market Drug Discovery Services Market Size (USD Bn.) 10 • Large Pharma companies to de-risk their supply chain by add
Slide 38: CDMO API market
CDMO API market CDMO API Market is estimated to grow at a CAGR of ~ 6%+ CDMO API Market Size (USD Bn.) Growth Drivers for API Market ~ 130 + • Although API market is dominated by the small molecules, higher growth is experienced by HPAPIs and large molecule segments 18 ~ 95 + 16 • Cost competitivene
Slide 39: End to end CRDMO services for drug substance in small molecules
CRDMO : Drug Discovery Services & API We provide end to end CRDMO services for drug substance in small molecules CRDMO - Drug Discovery Services CDMO CRDMO - API Integrated Chemistry Research Contract Development & Advanced Intermediate Drug Discovery Centre Innovation Centre Manufacturing Centre &
Slide 40: Drug Discovery Services: Three Pronged growth strategy
Drug Discovery Services Three Pronged growth strategy Add large Add Drive pharma customers capabilities CDMO • Formed a strategic partnership • Add large pharma customer • Drive CDMO: Building with Pierre Fabre to add segment and continue to be a capabilities in areas like development capabilities t
Slide 41: API: Maximize market penetration & transform operations
API Maximize market penetration & Transform operations by increasing cost effectiveness & asset utilisation Dominant position in select therapies • Comprehensive portfolio comprising of APIs from various therapeutic area - Central Nervous System, Cardiovascular System, Anti-infective and Anti- diabe
Slide 42: CRDMO results: DDS and API
CRDMO DDS: Continue to add large pharma clients ; Medium term outlook continues to be positive CRDMO API: Focus on profitable products ; Taking initiatives to reduce operating costs Drug Discovery Services Particulars ( Rs. Cr.) Q2’FY24 Q1’FY25 Q2’FY25 Y-o-Y H1'FY24 H1'FY25 Y-o-Y Drug Discovery Serv
Slide 43: Generics: Global market to grow at CAGR of 6%
5 Generics Global market to grow at a CAGR of 5 to 6% in the next 5 years Generics Market (USD Bn.) Overall Market • Overall market is growing on the back of increase in Chronic disease prevalence, loss of exclusivity for innovator products negated by pricing pressure in select markets ~ 532 Develop
Slide 44: Generics: Achieved profitability in Q2'FY25
Generics Achieved profitability in Q2’FY25 Key Products & Facilities • Therapeutic areas - Cardiovascular System, Central Nervous System, Gastrointestinal and Multi Specialty • Global presence with serving more than 50 countries including US, Europe, Canada, Japan, Australia and RoW • Building brand
Slide 45: Engineered turnaround by improving quality, optimizing cost
Generics Engineered turnaround by improving quality, optimizing cost & scaling Non US international business Continuous Continuous Scaled up Quality Improvement Cost Optimisation Non US International business Implemented a large scale quality Implemented cost optimization Scaled Non US international
Slide 46: Growth Strategy for key markets
Generics Growth Strategy for key markets Grow the profitable Build business in Focus on profitability in the Non-US International market Indian Market US Market • Focus on scaling 2 key markets • Build and Scale branded • Focus on profitable sustainable to triple digit revenue in INR Cr. generics bu
Slide 47: Generics: Achieved profitability in Q2'FY25
Generics Achieved profitability in Q2’FY25 Particulars ( Rs. Cr.) Q2’FY24 Q1’FY25 Q2’FY25 Y-o-Y H1'FY24 H1'FY25 Y-o-Y • Q2’FY25 revenue stable YoY • Q2’FY25 EBITDA sharply improved YoY due to Revenue 172 156 173 0% 375 328 (12%) overhead cost savings & profitable product mix. EBITDA (50) (11) 21 141
Slide 48: Proprietary Novel Drugs: Clinical stage precision therapeutics
6 Proprietary Novel Drugs Clinical stage precision therapeutics Advancing potent molecules to address unmet medical needs in Oncology & Auto immune diseases Lead Pre - Clinical Program Mechanism Indications Phase I /II Milestones Optimization (IND) ET(Essential Phase I data suggests thrombocythemia)
Slide 49: Key Indications for JBI-802
Proprietary Novel Drugs Key Indications for JBI - 802 Disease Indications Rationale JBI - 802 Response Non-Small cell lung cancer • STK11 mutation is observed in10-15% NSCLC (85 % of lung One patient with NSCLC having STK11 mutations showed (NSCLC) cancer is NSCLC). significant response on JBI-802,
Slide 50: Phase Two & Investigator led trials status for JBI-802
Proprietary Novel Drugs Phase Two & Investigator led clinical trials status for JBI-802 Key Indications Trial Status Company Sponsored Phase 2 trial ; First patient dosing done ; Interim data by 2025 • ET is a rare blood cancer that causes the bone marrow to produce too many platelets leading to str
Slide 51: Key Indications for JBI-778
Proprietary Novel Drugs Key Indications for JBI - 778; Disease Indications Rationale JBI – 778 Response Non-Small cell lung cancer • EGFR (epidermal growth factor receptor) mutations are • PRMT5 mechanism is relevant to EGFR inhibitor refractory (NSCLC) with or without brain observed in 10 - 50% of
Slide 52: Proprietary Novel Drugs: Continue to invest in a calibrated manner
Proprietary Novel Drugs Continue to invest in a calibrated manner • Continue to invest in a calibrated manner in two Particulars ( Rs. Cr.) Q2’FY24 Q1’FY25 Q2’FY25 Y-o-Y H1'FY24 H1'FY25 Y-o-Y lead programs Revenue 0 0 0 0 0 EBITDA (8) (6) (3) 63% (18) (9) 50% 47
Slide 53: Consolidated Reported Financials - Q2'FY25 & H1'FY25
Consolidated Reported Financials - Q2’FY25 & H1’FY25 Total Income growth (YoY) along with EBITDA margin expansion (YoY) Particulars ( Rs. Cr. ) Q2’FY24 Q1’FY25 Q2’FY25 Y-o-Y H1'FY24 H1'FY25 Y-o-Y • Q2’FY25 Total Income increased 5% YoY on Revenue 1,680 1,732 1,752 4% 3,267 3,484 7% the back of growt
Slide 54: Key Ratios
Key Ratios Net Debt / Ebitda continues to improve Particulars ( Rs. Cr. ) Mar 31, 2024 Sep 30, 2024 • Net Debt / Ebitda continues to improve Net Debt ( On constant currency, Net of DIC ) 2,457 1,736 Net Debt / Equity 0.46 0.30 Net Debt / EBITDA (TTM) 2.5 1.5 Exchange Rate : 1 USD = INR 83.41 on Mar
Slide 55: Sustainability
Sustainability Received KPMG ESG Excellence award for Mid / Small Cap category in the Pharma & Healthcare sector in Q2’FY25 Climate B Water B Supply Chain B Achieved 93 percentile Achieved 85 percentile 23709 patients consulted through 41.5 % reduction in Specific 22.5% reduction in Specific Water J
Slide 56: Summary – Q2'FY25
Summary – Q2’FY25 Radio Pharmaceuticals : New products and Ruby-Fill® maintaining growth momentum 1 Radio Pharmacies : Volume led growth & operational efficiencies maintaining margins Allergy Immunotherapy : Q2’FY25 EBITDA margins reduced due to lower revenue in the outside US markets & lower produc
Slide 57: Financial Results Table
Financial Results Table Total Income ( Rs. Cr. ) Q2’FY24 Q1’FY25 Q2’FY25 H1'FY24 H1'FY25 FY24 Revenue (A) 1,680 1,732 1,752 3,267 3,484 6,703 a. Radiopharma 741 832 820 1,432 1,652 3,001 Radiopharmaceuticals 251 262 251 455 513 952 Radiopharmacies 490 570 568 977 1,139 2,050 b. Allergy Immunotherapy
Slide 58: Annexure
Annexure
Slide 59: Executive Leadership Team
Executive Leadership Team Shyam S Bhartia Hari S Bhartia Priyavrat Bhartia Arjun S Bhartia Chairman Co-Chairman Managing Director Joint Managing Director Arvind Chokhany Shantanu Jha Dr. Tushar Gupta Group CFO, Group CHRO COO, CRDMO Head, Corporate Strategy 54 Whole-time Director
Slide 60: Executive Leadership Team
Executive Leadership Team Harsher Singh Kyle Ferguson Chris Preti CEO - Jubilant Radiopharma CEO – Allergy Business CEO - CDMO Giuliano Perfetti Dr. Jaidev Rajpal Dr. Syed Kazmi CEO - CRDMO, Biosys CEO - Jubilant Generics CEO - Jubilant Therapeutics 55
Slide 61: JPM Business Strategy
JPM Business Strategy To strengthen the unique position of each of the business unit to enhance shareholder value 1 2 3 4 5 6 INNOVATE STRENGTHEN GROW BUILD STEER DISCOVER Allergy CDMO PROPRIETARY Radiopharma Sterile Injectables CRDMO GENERICS Immunotherapy NEW DRUGS • Continue to grow • Gain share
Slide 62: Shareholding Pattern
Shareholding Pattern As on 30th Sep 2024 0.6% 25.2% Promoter and Promoter Group Domestic Institutions 50.7% Foreign Institutions Non - Institutions Employee Benefit Trust 17.9% 5.7% 57
Slide 63: Glossary
GLOSSARY Abbreviation Details Abbreviation Details CVS Cardiovascular System MEA Middle East Africa CNS Central Nervous System LATAM Latin America CDMO Contract Development Manufacturing Organization LOE Loss of exclusivity CRDMO Contract Research & Development Manufacturing Organization FDA (US) U.
Slide 64: For More Information
For More Information For Investors: Pankaj Dhawan Siddharth Rangnekar Jubilant Pharmova Limited CDR India Ph: +91 120 436 1105 Ph: +91 +91 9769919966 E-mail: [email protected] E-mail: [email protected] For Media: Ryan Marshall Sandipan Ghatak Madison Public Relations Phone: +91-120 436 10
Slide 65: Q2'FY25 Q&A
Q2’FY25 Q&A Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and ta
Slide 66: Radiopharmaceuticals Q&A
Radiopharmaceuticals Q1. Can you talk about growth in Ruby-Fill®? Answer: Ruby-fill® is a best in class Positron Emission Tomography (PET) radiopharmaceutical product used for Cardiac imaging through a non-invasive procedure of the myocardium, to evaluate regional myocardial perfusion in adult patie
Slide 67: Radiopharmaceuticals and Radiopharmacy Q&A
Q5. Can you explain Q2’FY25 Radiopharmaceutical results? Answer: Q2’FY25 Radiopharmaceuticals revenue is stable on YoY basis. Overall H1’FY25 sales grew by 13% on YoY basis on the back of new product sales in sulphur Colloid and growth in Ruby-Fill®. Q2’FY25 EBITDA decreased YoY due to change in pro
Slide 68: Allergy Immunotherapy and CDMO Sterile Injectable Q&A
regulatory strategy. We plan to invest in select markets with lower upfront investment. We plan to build market by market either through strategic partnerships, where our partner would hold market authorisation or build a local presence and hold market authorisation. Q9. Can you explain Q2’FY25 Alle
Slide 69: CDMO Sterile Injectable capacity Q&A
commercial production at Line 3 is expected to start post approval by FDA in late FY26 or early FY27. The revenue potential for Line 3 and Line 4 combined is estimated at USD 160 to 180 million. Typically, as seen in the Industry, it takes three to four years to reach optimal capacity utilisation po
Slide 70: CRDMO and Pierre Fabre partnership Q&A
expanded during last two years. As a testament, we on boarded two large pharmaceutical companies as our clients in FY24 and one more in Q2’FY25. We are well prepared to further scale up Infrastructure and scientific talent to take advantage of the upcoming in CRO demand. We expect revenue growth to
Slide 71: Generics Q&A
Answer: In our last update, we had communicated that we will try to achieve the breakeven by Q4’FY25. We are pleased to announce that we have achieved this sooner in Q2’FY25. The success of overall turnaround strategy is based on continuous quality improvement, reduction in overall cost and scaling
Slide 72: Proprietary Novel Drugs and consolidated financials Q&A
Q21. Why has the EBITDA losses halved in H1’FY25 as compared to H1’FY24? Answer: We are focussed on 2 key clinical stage projects and are investing in a calibrated manner. Consolidated Financials Q22. Will there be any further reduction in interest cost due to lowering of rates? Answer: We expect fi